Bicara Therapeutics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-138.0M | $-68.0M | $-52.0M |
| Depreciation & Amortization | — | — | — |
| Depreciation | $105.0K | $56.0K | $19.0K |
| Amortization | — | — | — |
| Stock-Based Compensation | $15.0M | $7.4M | $1.9M |
| Net Cash from Operating Activities | $-106.8M | $-74.8M | $-45.6M |
| Investing Activities | |||
| Capital Expenditures | $280.0K | $71.0K | $586.0K |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | $-318.5M | $-9.0K | $-586.0K |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $32.3M | $334.0M | $272.5M |
| Net Change in Cash | $-393.0M | $259.3M | $226.3M |
| Free Cash Flow | $-107.1M | $-74.8M | $-46.2M |